Worldwide Assessment of Deceased Donor Kidney Utilization
Part of paid clinical trials in Nashville, Tennessee.
- Sponsor
- Paris Translational Research Center for Organ Transplantation
- Study ID
- NCT07341516
- Status
- Enrolling By Invitation
Conditions
- Deceased Donor Kidney Transplant
- Kidney Failure
- Kidney Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The persistent imbalance between kidney transplant demand and organ availability remains a major global challenge. Optimizing the utilization of kidneys from deceased donors is a critical strategy to expand the donor pool and increase access to transplantation. Previous studies have demonstrated substantial international differences in kidney acceptance and discard practices, with significant potential gains in allograft life-years through optimized utilization. However, major changes in allocation policies, donor characteristics, preservation technologies, and global events such as the COVID-19 pandemic may have altered contemporary utilization patterns. This study aims to characterize international trends in deceased donor kidney utilization, compare allograft survival across countries, and estimate potential transplantable allograft life-years gained through improved utilization practices.
Key Dates
- Start date
- Nov 1, 2025
- Status verified
- Dec 2025
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 300,000 participants (estimated)
Primary Outcome Measure
Kidney allograft discard [ Time Frame: Day 0 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanderbilt Center for Transplant Science, Vanderbilt University Medical Center, Nashville, TN, USA | Nashville | Tennessee | 37232 | - |
Find similar trials in Nashville, TN
Related Studies
- Empagliflozin Treatment in Kidney Transplant RecipientsPHASE4 · Recruiting · VA Office of Research and Development · Hines, Illinois
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationPHASE3 · Recruiting · Alexion Pharmaceuticals, Inc. · Phoenix, Arizona
- Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister DonorPHASE1/PHASE2 · Recruiting · Jeffrey Veale, MD · Los Angeles, California
- Shingrix in Renal Transplant RecipientsPHASE3 · Recruiting · University of Colorado, Denver · Aurora, Colorado